5

10

ijŢ

l de

25

BM45324

LAPMS

- 1. An isolated polypeptide comprising an amino acid sequence/which has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4, over the entire length of SEQ ID NO:2 of SEQ ID NO:4 respectively.
- 2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4, over the entire length of SEQ ID NO:2 or SEQ ID NO:4 respectively.
- 3. The polypeptide as claimed in claim 1 comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4.
- 4. An isolated polypeptide having the amino acid sequence selected from the group े 📲 🛚 15 consisting of SEQ ID NO:2 or SEQ ID NO:4
 - 5. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic fragment is capable of raising an immune response (if necessary when coupled to a carrier) which recognises the polypeptide of SEQ ID NO:2 or SEQ ID NO:4.
 - 6. A polypeptide as claimed in any of claims 1 to 5 wherein said polypeptide is part of a larger fusion protein.
 - 7. An isolated polynuclestide encoding a polypeptide as claimed in any of claims 1 to 6.
- 8. An isolated polynucleotide comprising a nucleotide sequence encoding a polypepticle that has at least 85% identity to the amino acid sequence of SEQ ID NO:2 or 4 over the entire length of SEQ ID NO:2 or 4 respectively; or a nucleotide sequence complementary to said 30 isolated polynucleotide.


AMENDED SHEET

01-08-2000

5

30

BM45324



- 9. An isolated polynucleotide comprising a nucleotide sequence that has/at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2 or 4 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.
- 10. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1 or 3 over the entire length of SEQ ID NO:1 or 3 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.
- 10 11. The isolated polynucleotide as claimed in any one of claims 7 to 10 in which the identity is at least 95% to SEQ ID NO:1 or 3.
 - 12. An isolated polynucleotide comprising a nucleotide sequence encoding the polyneptide of SEQ ID NO:2 or SEQ ID NO:4.
 - 13. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1 or SEQ ID NO:3.
 - 14. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, SEQ ID NO:4 obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:3 or a fragment thereof.
- 15. An expression vector of a live microorganism comprising an isolated recombinant polynucleotide according to any one of claims 7 14.
 - 16. A host cell comprising the expression vector of claim 15 expressing an isolated polypeptide comprising an amino acid sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2 and SEQ ID NO:4, or a membrane of the host cell comprising the expressed polypeptide.

THE A MULLINGHERY WIL

17. A process for producing a polypeptide of claims 1 to 6 comprising culturing a host cell of claim 16 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

01819752441-

- 18. A process for expressing a polynucleotide of any one of claims 7 14 comprising 5 transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.
- 19. A vaccine composition comprising an effective amount of the polypeptide of any one 10 of claims 1 to 6 and a pharmaceutically acceptable carrier.
 - 20. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 7 to 14 and a pharmaceutically effective carrier.
 - 21. The vaccine composition according to either one of claims 19 or 20 wherein said composition comprises at least one other Netsseria meningitidis antigen.
 - 22. An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 6.
 - 23. A method of diagnosing a Neissefia meningitidis infection, comprising identifying a polypeptide as claimed in any one of claims 1 - 6, or an antibody that is immunospecific for said polypeptide, present within a biological sample from an animal suspected of having such an infection.
 - 24. Use of a composition comprising an immunologically effective amount of a polypeptide as claimed in any one of claims 1 - 6 in the preparation of a medicament for use in generating an immune response in an animal.

15

20

25

١, .[

01-08-2000

BM45324

- 25. Use of a composition comprising an immunologically effective amount of a polynucleotide as claimed in any one of claims 7 14 in the preparation of a medicament for use in generating an immune response in an animal.
- 5 26. A therapeutic composition useful in treating humans with Neisseria meningitidis comprising at least one antibody directed against the polypeptide of claims 1 6 and a suitable pharmaceutical carrier.

ADD AI

O'GG